Last reviewed · How we verify
ACT guided Routine Treatment — Competitive Intelligence Brief
marketed
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
ACT guided Routine Treatment (ACT guided Routine Treatment) — GlaxoSmithKline. ACT guided Routine Treatment is a clinical management strategy that uses Artemisinin-based Combination Therapy (ACT) with routine diagnostic testing to optimize malaria treatment outcomes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ACT guided Routine Treatment TARGET | ACT guided Routine Treatment | GlaxoSmithKline | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ACT guided Routine Treatment CI watch — RSS
- ACT guided Routine Treatment CI watch — Atom
- ACT guided Routine Treatment CI watch — JSON
- ACT guided Routine Treatment alone — RSS
Cite this brief
Drug Landscape (2026). ACT guided Routine Treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/act-guided-routine-treatment. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab